8-K: Genprex Advances Gene Therapies, Eyes 2026 Trial Data

Genprex, Inc. provides a corporate update detailing significant progress in its oncology and diabetes gene therapy programs, including ongoing clinical trials and preclinical advancements.

Summary

• Genprex issued a stockholder letter and corporate update summarizing recent achievements across its oncology and diabetes programs and outlining key milestones for 2025 and beyond.
• Patient treatment continues in the Phase 2a expansion portion of the Acclaim-1 clinical trial for late-stage non-small cell lung cancer (NSCLC), with interim analysis expected in the first half of 2026 after enrolling 19 patients by Q1 2026.
• Patient treatment continues in the Phase 2 expansion portion of the Acclaim-3 clinical trial for extensive stage small cell lung cancer (ES-SCLC), with interim analysis expected after the 25th patient reaches 18 weeks of follow-up in Q1 2026.
• REQORSA (quaratusugene ozeplasmid) has received FDA Fast Track Designation for both NSCLC and SCLC, and FDA Orphan Drug Designation for SCLC.
• Positive preclinical data for REQORSA were presented at the 2025 AACR meeting (KRASG12C mutant NSCLC), 2024 EORTC-NCI-AACR Symposium (mesothelioma, glioblastoma), and 2024 SITC Meeting (single agent immune response).
• The company expanded its intellectual property portfolio for REQORSA through new exclusive license agreements for mesothelioma, glioblastoma, and ALK-EML4 positive lung cancer.
• Progress in the diabetes program (GPX-002) includes finalizing construct components and ongoing preclinical studies at the University of Pittsburgh.
• Genprex plans to seek FDA guidance for Investigational New Drug (IND)-enabling studies for GPX-002 in the second half of 2025.
• Research is underway for a non-viral lipid nanoparticle delivery system for GPX-002, with preclinical data showing 100 times more luciferase activity in the pancreas than other organs.
• A wholly-owned subsidiary, Convergen Biotech, Inc., was formed to facilitate the intended separation of the diabetes program from the oncology program.
• Successful technology transfer of the GPX-002 manufacturing process to commercial CDMOs for current Good Manufacturing Practices (cGMP) compliant production was achieved.

Sentiment

Score: 7

Explanation: The filing presents a highly positive and proactive outlook, detailing significant clinical and preclinical advancements, intellectual property expansion, and strategic corporate restructuring. The ongoing patient enrollment in trials, positive preclinical data, and progress in manufacturing are strong indicators of operational momentum. However, the explicit mention of the need for capital to maintain Nasdaq listing and continue as a going concern introduces a notable financial risk, tempering the overall positive sentiment.

Positives

• Achieved multiple clinical development milestones in 2025, demonstrating active progress in its pipeline.
• REQORSA was generally well tolerated with no dose limiting toxicities in Phase 1 of both Acclaim-1 and Acclaim-3 trials.
• Early signs of efficacy observed in Acclaim-1 Phase 1, including prolonged progression-free survival and one partial response.
• Received FDA Fast Track Designation for both NSCLC and SCLC programs, potentially accelerating regulatory review.
• Received FDA Orphan Drug Designation for the SCLC program, providing incentives and market exclusivity upon approval.
• Expanded intellectual property portfolio for REQORSA through new exclusive license agreements for mesothelioma, glioblastoma, and ALK-EML4 positive lung cancer.
• Positive preclinical data for REQORSA in various difficult-to-treat cancers (KRASG12C mutant NSCLC, mesothelioma, glioblastoma, ALK-positive lung cancer) suggest broad therapeutic potential.
• Significant progress in the diabetes program (GPX-002), including finalized construct components and successful technology transfer for cGMP manufacturing.
• Positive preclinical data for GPX-002 in non-human primate (NHP) models showed improved glucose tolerance and reduced insulin requirements.
• Research into a non-viral lipid nanoparticle delivery system for GPX-002 offers potential for re-dosing patients and positions the company as a leader in gene therapy.
• Formation of Convergen Biotech, Inc. is a strategic move to enhance focus and potentially attract direct investment for the diabetes program.

Risks

• Ability to advance the clinical development, manufacturing, and commercialization of product candidates in accordance with projected timelines and specifications.
• Timing and success of clinical trials, intended regulatory submissions, and any resulting regulatory approvals are uncertain.
• The effect of product candidates, alone and in combination with other therapies, on cancer and diabetes may not be as anticipated.
• Future growth and financial status, including the ability to maintain compliance with Nasdaq Capital Market listing requirements and to continue as a going concern.
• Ability to obtain capital to meet long-term liquidity needs on acceptable terms, or at all.
• Commercial and strategic partnerships, including third-party vendors, suppliers, and manufacturers, may not successfully perform and scale up manufacturing.
• Intellectual property and licenses may not provide adequate protection or may be challenged.
• Current expectations, estimates, forecasts, and projections about the industry and markets may prove inaccurate.
• Immunosuppression (IS) is necessary for several months in NHP models for GPX-002 to prevent anti-viral immunity, which may imply complex patient management in human trials.

Future Outlook

Genprex anticipates advancing its oncology and diabetes clinical programs, with key milestones expected in the second half of 2025 and beyond, including interim analyses for lung cancer trials in the first half of 2026 and seeking FDA guidance for its diabetes program. The company believes it is at a momentous inflection point, aiming to expand its clinical development pipeline and enhance stockholder value through strategic initiatives.

Management Comments

• "Genprex has made significant progress across our technology programs this past year, and I am enthusiastic about Genprexs future as we continue to advance our clinical development program while maintaining streamlined, focused strategies that are important to build value across the entire company."
• "We remain dedicated to transforming lives of patients battling cancer and diabetes through our novel gene therapies, and we look forward to executing on a number of upcoming milestones in the second half of 2025 and beyond."
• "I believe in our innovative approaches: reintroducing tumor suppressor genes to combat cancer and revitalizing insulin-producing cells to stabilize glucose levels in diabetes."
• "With multiple FDA Fast Track Designations and promising clinical trial results, Genprex is at the forefront of medical advancements, striving to bring hope and improved outcomes to patients worldwide."
• "We have never had a time in our Company history where we have had such a robust pipeline. I am confident in the technology achievement weve made to date, and I believe we are at a momentous inflection point for Genprex as we execute our strategic plans for the company and achieve potentially value-creating milestones ahead of us."

Industry Context

Genprex operates in the highly innovative and competitive gene therapy sector, focusing on oncology and diabetes, areas with significant unmet medical needs. Its strategy of combining gene therapy with existing standard-of-care treatments (e.g., Tagrisso, Tecentriq) is a common approach to enhance efficacy and overcome resistance. The exploration of non-viral lipid nanoparticle delivery systems for its diabetes program aligns with a broader industry trend to address limitations of traditional viral vectors, such as re-dosing challenges and immune responses, positioning Genprex at the forefront of next-generation gene therapy delivery.

Comparison to Industry Standards

• REQORSA's FDA Fast Track Designation for both NSCLC and SCLC, and Orphan Drug Designation for SCLC, are significant regulatory advantages that can expedite development and review compared to typical drug development pathways, aligning with accelerated programs seen in other innovative biotech companies.
• The company's collaboration with world-class institutions like The University of Texas MD Anderson Cancer Center, University of Pittsburgh, New York University Langone Health, UTHealth Houston, and University of Michigan Rogel Cancer Center is a standard and effective strategy for clinical-stage biotech firms to leverage leading research expertise and expand intellectual property.
• The reported preclinical data for REQORSA overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts demonstrates a potential solution to a significant challenge in targeted cancer therapy, where acquired resistance is a common issue for drugs like sotorasib (Amgen's Lumakras) and other KRAS inhibitors.
• Genprex's research into a non-viral lipid nanoparticle (LNP) delivery system for GPX-002, particularly its claim of being the 'first and only company to be doing this type of research in the pancreatic duct using an LNP,' suggests a potentially differentiated approach compared to many gene therapy companies that primarily rely on adeno-associated virus (AAV) vectors, offering a competitive edge in re-dosing capabilities.
• The successful technology transfer of GPX-002 manufacturing to cGMP compliant facilities is a critical step for clinical-stage companies, demonstrating readiness for larger-scale production and adherence to regulatory standards, comparable to established biotech firms preparing for later-stage trials.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased value through clinical progress, expanded intellectual property, and strategic corporate restructuring, but also face dilution risk due to the stated need for future capital raises.
• **Patients**: Continued development of novel gene therapies offers hope for improved treatment options for cancer and diabetes, particularly for those with limited current options.
• **Employees**: Ongoing and expanding research and development activities provide continued employment and opportunities within the company.
• **Collaborators/Partners**: Strengthened and new collaborations with academic institutions and contract development and manufacturing organizations (CDMOs) indicate continued partnership opportunities and shared scientific advancement.
• **Creditors**: The explicit mention of needing to obtain capital to meet long-term liquidity needs and continue as a going concern highlights potential financial risk.

Next Steps

• Complete Acclaim-1 Phase 2 expansion enrollment for interim analysis (19 patients) by the end of the first quarter of 2026.
• Report on Acclaim-1 interim analysis in the first half of 2026.
• Complete enrollment of the first 25 patients for interim analysis in the Acclaim-3 Phase 2 expansion portion in the first quarter of 2026.
• Seek FDA guidance for the preclinical studies needed to file an Investigational New Drug (IND) application and initiate first-in-human studies for GPX-002 in the second half of 2025.
• Continue preclinical studies of GPX-002 in NHP models of both Type 1 and Type 2 diabetes, evaluating viral efficacy after six months of immunosuppression.
• Expand the clinical development pipeline with future clinical studies within the scope of licensed patents.
• Execute strategic plans for the company to achieve potentially value-creating milestones.

Key Dates

Recommendation

Genprex is demonstrating tangible progress in its clinical and preclinical gene therapy pipeline, with positive early efficacy signals in lung cancer trials and promising preclinical data across multiple cancer types and diabetes. The strategic formation of a subsidiary and the pursuit of a non-viral delivery system for diabetes therapy are forward-looking moves. However, the company is still in early to mid-stage clinical development, which inherently carries high risk. Crucially, the filing explicitly highlights the need to obtain capital to meet long-term liquidity needs and maintain Nasdaq listing, indicating a 'going concern' risk. This combination of scientific promise and significant financial uncertainty warrants a 'hold' recommendation, advising investors to monitor the company's progress closely while acknowledging the high-risk, high-reward profile and the critical need for future financing.

Keywords

Gene therapy, Oncology, Diabetes, Lung cancer, NSCLC, SCLC, REQORSA, GPX-002, Clinical trials, Preclinical data, FDA Fast Track, Orphan Drug, Biomarker, Lipid nanoparticle, AAV vector, Intellectual property, Biotechnology